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Remain cautious in prescribing statins for
those with nonalcoholic steatohepatitis
It is encouraging to see that statins may not
worsen nonalcoholic steatohepatitis (NASH)
and can potentially improve the process.
However, these conclusions are supported
by small clinical trials, and clinicians should
remain cautious in prescribing statins for
patients with NASH.
Importantly, if liver enzyme elevations are
revealed during baseline examinations,
consider statins only if a systematic work-up
is unrevealing and suggests only NASH.7–9
However, I generally avoid statins for those
with more than mild to moderate elevations
(greater than 100). Before starting statins,
I inform patients of the small but potential
risk of worsening hepatotoxicity and the
importance of close follow-up. If the patient
is agreeable, obtaining hepatic enzymes after
each statin dose change and periodically
after cholesterol goals are achieved is 
integral in the successful management of
the NASH patient requiring statin therapy.
Robert C. Oh, MD, MPH
Department of Family Medicine,
Tripler Army Medical Center, Honolulu, Hawaii
C L I N I C A L C O M M E N TA R Y
E V I D E N C E - B A S E D A N S W E R
Patients with steatohepatitis who take HMG
Co-A reductase inhibitors (statins) lower
their elevated liver enzymes and show 
evidence of improvement in fatty liver on 
follow-up imaging (strength of recommen-
dation [SOR]: C, based on very small,
short-term prospective studies).
Statins do not further increase 
transaminase levels for patients with 
pre-existing transaminase elevations 
(SOR: B, based on 2 retrospective cohort
studies). However, for patients with 
decompensated liver disease or advanced
cirrhosis, balance the benefits of statins
against the risks (SOR: C, based on 
expert opinion).
z Evidence summary
A prospective study1 evaluated 5 patients
with biopsy-confirmed nonalcoholic
steatohepatitis (NASH) who took 20 mg
of pravastatin daily for 6 months. Liver
enzyme levels at baseline were no more
than 3 times the upper limit of normal. All
5 patients had normalized liver enzymes at
the end of the study.
A 6-month unblinded study2 found sim-
ilar results among 44 adult patients with
biopsy-confirmed NASH. Twenty-seven
hyperlipidemic patients (aged 50 ± 1.4 years)
with an average alanine aminotransferase
(ALT) of 81.8 U/L took 10 mg of atorva-
statin daily. Seventeen normolipidemic
patients (aged 43.7 ± 1.8 years) with an
average ALT of 76.0 U/L took ursodeoxy-
 
Copy
right
® Dow
den H
ealth
 Med
ia  
For p
erson
al us
e onl
y
For mass reproduction, content licensing and permissions contact Dowden Health Media.
cholic acid (UDCA) 13–15 mg/kg/d for the
same duration; 59% of atorvastatin-treated
patients normalized liver enzyme levels
compared with 23% in the UDCA group.
On computed tomography scanning, both
groups showed improvement in liver densi-
ties, suggesting improvement of fatty liver.2
Another study3 included patients with
biopsy-confirmed fatty liver and elevated
ALT levels greater than 1.5 times the 
upper limit of normal. In this 24-week
study, 23 predominantly hypertriglyceri-
demic patients took omega-3 fatty acids, 
5 mL 3 times daily, 28 hypercholes-
terolemic patients took atorvastatin 20 mg
daily, and 21 dyslipidemic patients with a
body mass index >27.0 took orlistat 120
mg 3 times daily. ALT levels decreased in
all 3 groups during the study. Ultrasono-
graphy showed normal liver echo pattern
at the end of treatment for 35% of omega-
3 patients, 61% of atorvastatin patients,
and 86% of orlistat patients. No serious
adverse events were observed.
Two retrospective studies of patients
with baseline elevated transaminases who
took statins showed no significant increase
in transaminase levels during treatment
compared with patients with elevated
transaminases who did not take statins.
One study4 reviewed electronic medical
records for patients with preexisting ele-
vated liver enzymes who initiated statin
therapy (atorvastatin, simvastatin, or 
fluvastatin) and had follow-up labs drawn
6 months later (cohort 1, n=342). The
comparison groups included patients with
normal liver enzymes who initiated statins
(cohort 2, n=1437) and patients with ele-
vated baseline liver enzymes who did not
take statins (cohort 3, n=2245). At follow-
up, 4.7% of cohort 1 patients had mild-to-
moderate elevations in liver enzymes,
which did not differ significantly (P=.2)
from those in cohort 3. Within cohort 2,
1.9% experienced mild-to-moderate eleva-
tions of transaminases (defined as less than
10 times the upper limit of normal).
Another retrospective cohort study5 of
patients with preexisting elevated liver
enzymes found comparable results with
lovastatin. Among lovastatin patients
(n=135), 6.6% had mild-to-moderate ele-
vations in transaminases during therapy vs
11% of the cohort of patients with pre-
existing elevated liver enzymes who did not
take statins. This difference was not statis-
tically significant (P=.2).
Recommendations from others
The National Cholesterol Education
Project6 states that “the incidence of clini-
cally important transaminase elevations in
the large statin trials is the same for statins
as for placebo. Progression to liver failure
is exceedingly rare, if it occurs.” They fur-
ther state that the use of statins for persons
with decompensated liver disease or
advanced cirrhosis depends on clinical
judgment, but that their use in NASH is
considered safe. 
The FDA states that statins are con-
traindicated in cholestasis and active liver
disease, and that statins should be discon-
tinued when liver enzymes increase to 3
times the upper limits of normal.
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Inform patients 
of the small risk 
of worsening liver
toxicity and 
the importance 
of close follow-up
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